U.S. FDA Highlights Hands-On Approach To China Inspections In Budget Plan
This article was originally published in PharmAsia News
Executive Summary
The inspection focus of U.S. FDA’s budget request is largely on adding more personnel, but the agency continues to think about how best to target and leverage its resources in its globalization plan.
You may also be interested in...
FDA's Projected $20 Mil. In 2013 Biosimilar User Fees Translates Into 68 More Staffers
Administration’s proposed fiscal year 2013 spending plan includes $4.5 billion for FDA, with $2 billion or 44% provided by various user fees.
Inspection Fees Face Tough Road In Congress As PhRMA Remains Opposed
At user fee hearing, PhRMA’s Wheadon counters questions from Rep. Dingell, saying FDA already is receiving resources to conduct GMP inspections outside the U.S.
Foreign Regulator Exchange Program Contemplated By U.S. State Department
FDA has its own programs, but a State Department undersecretary said enhancing training at FDA could boost efforts to fight drug counterfeiting and diversion.